Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Nov;272(5):814-819.
doi: 10.1097/SLA.0000000000004184.

Adverse Biology in Adenocarcinoma of the Esophagus and Esophagogastric Junction Impacts Survival and Response to Neoadjuvant Therapy Independent of Anatomic Subtype

Noel E Donlon  1 , Jessie A Elliott, Claire L Donohoe, Conor F Murphy, Tim Nugent, Brendan Moran, Sinead King, Narayanasamy Ravi, John V Reynolds
Affiliations

Adverse Biology in Adenocarcinoma of the Esophagus and Esophagogastric Junction Impacts Survival and Response to Neoadjuvant Therapy Independent of Anatomic Subtype

Noel E Donlon et al. Ann Surg. 2020 Nov.

Abstract

Objective: The aim of this study was to propose and test a novel adverse pathology classification in AEG.

Background: Recent scientific advances show genomic and molecular concordance across all AEG types, suggesting a rationale for a biologic classification. We tested a 3-dimension adverse pathology classification across the entire junction and per Siewert anatomic subtype.

Methods: Of 1625 patients with AEG, 650 underwent radical surgery, 55% post-neoadjuvant therapy (NeoT). Adverse features defined a priori were poor differentiation (PD), lymphatic invasion (LI), vascular invasion (VI), and perineural invasion (PN), with 3 groupings: 0 (no adverse feature), 1 to 2, and 3 to 4. Multivariable logistic and Cox proportional hazards regression were applied.

Results: For adverse pathology, 31%, 46%, and 23% had 0, 1 to 2, and 3 to 4, respectively. Fifty percent of cases were AEG I, 25% AEG II, and 25% AEG III. Median survival was not reached, 49 and 17 months for 0, 1 to 2, and 3 to 4 adverse pathology, respectively (P < 0.001), and 76, 51, and 34 months for AEG I, II, and III, respectively (P < 0.001); AEG I was significantly (P< 0.001) associated with lower c (y)pT and c (y)pN stages, and LI, VI, PN, and PD (poor vs other). The pathology model was significant for survival along with (y)pT and (y)pN, and predicted response to chemotherapy and chemoradiation irrespective of anatomic subtype (P < 0.001).

Conclusion: A novel classification using standard pathology as proxy for poor biology is associated with survival and response to therapy. This effect is observed across the entire AEG spectrum, highlighting how biology should be aligned with anatomy in the modern paradigm of AEG management and design of clinical trials.

PubMed Disclaimer

References

    1. Siewert JR, Hölscher AH, Becker K, et al. Cardia cancer: attempt at a therapeutically relevant classification. Chirurg 1987; 58:25–32.
    1. Siewert JR, Stein HJ. Classification of adenocarcinoma of the oesophagogastric junction. Br J Surg 1998; 85:1457–1459.
    1. American Joint Committee on Cancer Staging Manual. 6th ed.New York, NY: Springer; 2002.
    1. Siewert JR, Feith M, Werner M, et al. Adenocarcinoma of the esophagogastric junction; results of surgical therapy based on anatomical/topographic classification of 1,002 consecutive patients. Ann Surg 2000; 232:353–361.
    1. Hölscher AH, Law S. Esophagogastric junction adenocarcinomas: Individualization of resection with special considerations for Siewert Type II, and Nishi Types EG, E=G, and GE cancers. Gastric Cancer 2020; 23:3–9.

LinkOut - more resources